Previous studies showed that compensated cirrhosis patients treated with IFN had comparable or even better response and a similar side effect profile as those without cirrhosis, with reduced risk of hepatic decompensation, HCC and prolonged survival in responders. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.